1

1 **TITLE:** Titin-Truncating variants Predispose to Dilated Cardiomyopathy in Diverse 2 Populations

3 4

Authors: John DePaolo, MD, PhD,¹ Marc Bornstein, AB,² Renae Judy, MS,¹ Sarah
Abramowitz, BA,¹ Shefali S. Verma, PhD,³ Michael G. Levin, MD,^{2,4} Zoltan Arany, MD,
PhD,^{2*} Scott M. Damrauer, MD,^{1,2,4,5*}

8

9 Affiliations:

- ¹ Department of Surgery, Perelman School of Medicine, University of Pennsylvania,
 Philadelphia, PA 19104, USA.
- ² Cardiovascular Institute, Department of Medicine, Perelman School of Medicine,
- 13 University of Pennsylvania, PA 19104, USA.
- ³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine,
- 15 University of Pennsylvania, PA 19104, USA.
- ⁴ Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
- ⁵ Department of Genetics, Perelman School of Medicine, University of Pennsylvania,
- 18 Philadelphia, PA 19104, USA.
- 19 * Jointly supervised this work
- 20
- 21 **Text Word Count**: 2704
- 22 **References**: 25
- 23 **Tables**: 1
- 24 **Figures**: 3
- 25

26

27 Address for correspondence:

- 28 Scott Damrauer, MD
- 29 Perelman School of Medicine
- 30 Division of Vascular Surgery
- 31 Hospital of the University of Pennsylvania
- 32 3400 Spruce Street, 14th Floor South Perelman Center
- 33 Philadelphia, PA 19104
- 34 Office: 215-615-1698
- 35 scott.damrauer@pennmedicine.upenn.edu
- 36

2

37 Key Points

- 38 **Question:** Do high percentage spliced in (hiPSI) titin truncating variants (TTNtvs) confer
- 39 similar levels of risk for dilated cardiomyopathy (DCM) across diverse populations?
- 40 **Findings:** In a cohort study that comprised 43,731 individuals of diverse genetic
- 41 background with electronic health records linked to whole exome sequencing data,
- 42 hiPSI TTNtvs conferred increased risk of DCM across all individuals irrespective of
- 43 genetic background as measured by genetic distance from the 1000 Genomes Project
- 44 European centroid.
- 45 **Meaning:** The findings of this study suggest that TTNtvs increase risk of DCM among
- 46 individuals independent of genetic background and that genetic similarity to a reference
- 47 population should not play a role in screening for genetic causes of dilated
- 48 cardiomyopathy.

3

50 Abstract

- 51 **Importance**: The effect of high percentage spliced in (hiPSI) *TTN* truncating variants
- 52 (TTNtvs) on risk of dilated cardiomyopathy (DCM) has historically been studied among
- 53 population subgroups defined by genetic similarity to European reference populations.
- 54 This has raised questions about the effect of TTNtvs in diverse populations, especially
- among individuals genetically similar to African reference populations.
- 56 **Objective**: To determine the effect of TTNtvs on risk of DCM in diverse population as
- 57 measured by genetic distance (GD) in principal component (PC) space.
- 58 **Design:** Cohort study
- 59 **Setting:** Penn Medicine Biobank (PMBB) is a large, diverse biobank.
- 60 **Participants**: Participants were recruited from across the Penn Medicine healthcare
- 61 system and volunteered to have their electronic health records linked to biospecimen
- 62 data including DNA which has undergone whole exome sequencing.
- Main Outcomes and Measures: Risk of DCM among individuals carrying a hiPSI
 TTNtv.

Results: Carrying a hiPSI TTNtv was associated with DCM among PMBB participants
across a range of GD deciles from the 1000G European centroid; the effect estimates
ranged from odds ratio (OR) = 3.29 (95% confidence interval [CI] 1.26 to 8.56) to OR =
9.39 (95% CI 3.82 to 23.13). When individuals were assigned to population subgroups
based on genetic similarity to the 1000G reference populations, hiPSI TTNtvs conferred

4

- significant risk of DCM among those genetically similar to the 1000G European
- 71 reference population (OR = 7.55, 95% CI 4.99 to 11.42, *P*<0.001) and individuals
- 72 genetically similar to the 1000G African reference population (OR 3.50, 95% CI 1.48 to
- 73 8.24, *P*=0.004).
- 74 Conclusions and Relevance: TTNtvs are associated with increased risk of DCM
- 75 among a diverse cohort. There is no significant difference in effect of TTNtvs on DCM
- risk across deciles of GD from the 1000G European centroid, suggesting genetic
- 57 background should not be considered when screening individuals for titin-related DCM.

5

79 Introduction

80 Titin, the protein encoded by the TTN gene, is the largest protein in the human 81 body. It is found in the sarcomere where it spans from the Z-disk to the M-band, and is critical for sarcomere assembly, contraction and relaxation in striated cardiac muscle.¹ 82 83 In populations largely composed of individuals genetically similar to the 1000 Genomes 84 Project (1000G) European reference population (EUR), heterozygous TTN truncating 85 variants (TTNtvs) that encode for shortened forms of the titin protein have been 86 identified as a common genetic cause of dilated cardiomyopathy (DCM). These TTNty have been associated with 25% of familial cases of DCM, and 10-20% of sporadic 87 88 cases.²⁻⁷ Only variants located in exons that are highly likely to be spliced into adult 89 cardiac TTN transcripts, known as high percentage spliced in (hiPSI) variants, are pathogenic.³ hiPSI TTNtvs may cause DCM by reducing abundance of full-length TTN 90 91 protein (haploinsufficiency) and/or through dominant negative effects.^{8,9} 92 We previously demonstrated the association of hiPSI TTNtvs with DCM 93 exclusively in EUR individuals, but were unable to detect an association between hiPSI 94 TTNtvs and DCM among Penn Medicine Biobank (PMBB) participants genetically 95 similar to the 1000G African reference population (AFR: odds ratio [OR] 1.8, 95% CI 0.2 to 13.7, P=0.57), or among AFR participants of the Jackson Heart Study.⁷ Recently, a 96 97 cross-sectional analysis of individuals with DCM demonstrated a statistically significant 98 but attenuated effect of predicted loss-of-function (pLOF) variants in TTN among AFR 99 individuals compared to EUR individuals, potentially underscoring the limitations of 100 applying genetic understanding of disease derived from a single ancestry group to diverse populations.¹⁰ 101

6

102 Common and rare genetic risk factors for disease have historically been analyzed among different populations separated by ancestry.¹¹⁻¹⁴ This reflects the belief 103 104 that the artificial grouping of individuals into genetically common cohorts allows 105 improved assignment of genetic risk. However, greater understanding of genetic 106 similarities between groups of individuals combined with the results of genetic admixture 107 within different populations suggests that instead of strict dichotomization into groups, genetic ancestry is better thought of as a continuum of relative similarity.¹² 108 109 Here we describe the assessment of DCM risk conferred by hiPSI TTNtvs in a 110 large, diverse biobank. Instead of using genetic similarity to group individuals together, 111 each participant's genetic distance (GD) from the 1000G European centroid was 112 calculated and risk of DCM was assessed across a range of genetic distances. As a 113 sensitivity analysis, participants were assigned an "population group" according to their 114 genetic similarity to one of the 1000G continental-level reference populations and risk of 115 DCM was stratified by "genetic similar" group. Due to previous research identifying TTNtvs risk factors for atrial fibrillation (Afib),¹⁵⁻¹⁷ we performed a similar investigation 116 117 into the link between TTNtvs and Afib.

118

119 Methods

120 Study Population

121 The Penn Medicine BioBank is a genomic and precision medicine cohort 122 comprising participants who receive care in the Penn Medicine health system and who 123 consent to linkage of electronic health records with biospecimens, including 43,731 with 124 DNA which has undergone whole exome sequencing (pmbb.med.upenn.edu). As

7

125	previously described, ⁷ DCM was defined either as ≥ 2 outpatient or ≥ 1 inpatient						
126	encounters with: 1) the International Classification of Diseases, 10 th Revision (ICD10)						
127	diagnosis code of I42.0; or 2) ICD10 codes I42.8 or I42.9 or the International						
128	Classification of Diseases, Ninth Revision (ICD9) codes 425.4, 425.8, or 425.9, and						
129	mention of "dilated cardiomyopathy" or "DCM" in free text encounter notes. Ischemic						
130	cardiomyopathy (ICM) was defined as ≥ 2 outpatient or ≥ 1 inpatient encounters with						
131	ICD10 codes I24 or I25, or ICD9 codes 411 or 414. Afib was defined as \geq 2 outpatient or						
132	\geq 1 inpatient encounters with ICD10 codes I48, I48.1, I48.2, or I48.9, or ICD9 codes						
133	427.2 or 427.21. A total of 9,020 individuals in PMBB had transthoracic						
134	echocardiography (TTE) data available that included left ventricular ejection fraction						
135	(LVEF).						
136	Genetic Data						
137	Whole exome sequencing was performed as previously described by Regeneron						
138	Genomics Center. ¹⁸ Individual patient DNA samples were processed and sequenced on						
139	the Illumina NovaSeq 6000 (Albany, NY, USA). WeCall variant caller (v2.0.0) was						
140	employed for sequence alignment (GRCh38), variant identification, and genotype						
141	assignment. Quality control exclusions included sex errors, high rates of heterozygosity						
142	(D-statistic > 0.4), low sequence coverage, and genetically identified sample duplicates.						
143	Single nucleotide variants (SNVs) were filtered for a read depth \geq 7 and were retained if						
144	they either had at least one heterozygous variant genotype with an allele balance ratio						
145	\geq 0.15, or a homozygous variant genotype. ¹⁹ Insertion-deletion variants (INDELs) were						

146 filtered for a read depth \geq 10 and either a heterozygous variant genotype with an allele

147 balance \geq 0.20, or a homozygous variant genotype.

8

148 TTN Truncating Variant Calls

149 TTNtvs were filtered for minor allele frequency < 0.001 and selected based on 150 predicted loss of function, truncating variants using ANNOVAR.²⁰ Splice site variants 151 were screened for those affecting canonical donor or acceptor splice sites (two bases 152 flanking either exon). Variants were considered hiPSI if percent spliced in was greater 153 than 90% (PSI>0.9).³

154 Genetic Distance

155 To consider differences in genetic ancestry along a continuous scale, genetic distance (GD) from the 1000G European centroid was calculated as previously 156 decribed.¹⁴ Briefly, the 43,731 individuals in the PMBB were projected onto the 1000G²¹ 157 158 principal component (PC) space. The GD was calculated by taking the Euclidean 159 distance for each individual from the 1000G European centroid using the equation $d_i = \sqrt{\sum_{j=1}^{J=10} (pc_{ij} - pc_{Ej})^2}$ where pc_{ij} is the *j*th PC of individual *I*, pc_{Ej} is the 1000G 160 161 European mean of the *i*th PC, and *J* is set to 10. GD was used to bin each individual in 162 PMBB into deciles from the closest 10% to the European centroid to the furthest 10% 163 from the European centroid.

164 Statistical Analysis

Logistic regression was employed to evaluate the association of hiPSI TTNtvs with prevalent DCM adjusting for age and sex. Linear regression was used to assess the effect of hiPSI TTNtvs on minimum left ventricular ejection fraction (LVEF) adjusting for age and sex. Statistical analyses were performed using R (version 4.2.0).

169

9

171 <u>Results</u>

172 Study Population

There were 43,371 participants in the analytic cohort (**Table 1**). The median age at analysis was 57 years (IQR: 45-69 years) and 21,907 (50%) were female. One percent (436 individuals) carried a hiPSI TTNtv, 1,112 individuals (2.5%) had a DCM diagnosis, and 4,920 individuals (11%) had an Afib diagnosis. There were 365 unique TTNtvs identified including 174 stop-gains, 44 frameshifting insertion-deletions, and 147 essential splice site variants.

179 Calculating genetic distance

180 GD as the calculated Euclidean distance provides a method to assess the risk of 181 DCM conferred by TTNtvs across a genetically diverse population without relying on 182 artificial grouping based on genetic similarity to a reference panel. Euclidean distance is the distance between two points in nth-dimensional space. The vast majority of 183 184 understanding of the genetic risk of DCM, including that conferred by TTNtvs, was 185 derived from investigation of cohorts primarily comprised of individuals genetically 186 similar to the 1000G European reference population. Integrating the genetic distance 187 from the 1000G European centroid into the analysis of DCM risk among TTNtv carriers 188 accounts for population differences between individuals and the cohort from which 189 genetic understanding of disease has been derived. Therefore, GD provides two useful 190 tools in the current analysis: 1) a method to treat genetic similarity as a continuum 191 rather than an artificially dichotomized value; and 2) a way to test if decreasing genetic 192 similarity indicates a change in TTNtv-derived DCM risk that might support previous 193 findings of differing effects among genetically dissimilar groups.

194	GD was calculated for each individual in PMBB and genetic diversity by GD was
195	compared to categorical assignment to population subgroups similar to the 1000G
196	reference populations based on PC analysis (Figure 1A-D). To demonstrate the extent
197	of genetic admixture and the arbitrary nature of grouping individuals genetically similar
198	to reference populations, PMBB individuals were compared to 1000G reference panel
199	individuals based on PC analysis (Figure 1E-G). Individuals were then binned by GD
200	decile; each decile included a range of individuals genetically similar to a 1000G
201	reference population (Supplemental Table 1) and PC analysis by GD decile
202	redemonstrated the extent of genetic admixture (Supplemental Figure 1). Together
203	these analyses characterize the genetic heterogeneity in the PMBB population.
204	
205	Effect of TTNtvs on risk of DCM across genetic distances
206	In the population overall, there is a 5.6-fold increased risk of DCM conferred by
207	carrying a TTNtv when adjusting for age, sex, and the first five genetic PCs
208	[Supplemental Table 2]. To determine the effect of TTNtvs on DCM risk at different
209	GDs from the European centroid, logistic regression analysis was performed among
210	PMBB individuals binned by GD decile adjusting for age and sex within each bin.
211	Among those individuals closest to the 1000G European centroid by GD, hiPSI TTNtvs
212	were associated with DCM (Decile 1 OR = 5.82, 95% CI 2.42 to 14.01, <i>P</i> <0.001)
213	[Figure 2A]; there was no significant effect decomposition as GD decile increased
214	(Decile 10 OR = 9.39, 95% CI 3.82 to 23.13, <i>P</i> <0.001). Meta-analysis of binned
215	results demonstrated an overall OR = 5.42 (95% CI 4.01 to 7.32, P<0.001); there
216	was no evidence of significant heterogeneity ($I^2=0\%$, $\chi^2=4.59$, <i>P</i> =0.87). This was

11

217	supported by a second analysis among all participants in which either GD from the
218	1000G European centroid alone nor the interaction between GD and hiPSI TTNtvs had
219	a statistically significant effect on the risk of DCM (Supplemental Table 2). Taken
220	together these results suggest that GD does not alter DCM risk. Similarly, there was no
221	evident trend of greater or lesser effect on minimum LVEF as GD increased (Figure
222	2B), though there was a trend towards increased heterogeneity (I^2 =42%, χ^2 =15.48,
223	P=0.08). We conclude that hiPSI TTNtvs associate with increased DCM risk and
224	reduced minimum LVEF across diverse populations.
225	
226	Comparison to categorical assignment of genetic diversity
227	We previously demonstrated a significant effect on DCM risk conferred by
228	carrying TTNtvs among individuals genetically similar to the 1000G EUR reference
229	population, however could not detect an effect among individuals genetically similar to
230	the 1000G AFR reference population. ⁷ In this updated study, encompassing a
231	substantially larger number of participants, we evaluated the effect of TTNtvs among
232	individuals artificially separated into groups to compare both to our previous published
233	results and to the results above. Carrying a hiPSI TTNtv was associated with DCM
234	among individuals genetically similar to the 1000G EUR reference population, whether

including (Supplemental Figure 2) or excluding individuals with ischemic

236 cardiomyopathy [ICM] (odds ratio [OR] 7.55, 95% CI 4.99 to 11.42, *P*<0.001) [Figure

3A]. Similar, but attenuated, results were observed among individuals genetically similar

238 to the 1000G AFR reference population (OR 3.50, 95% CI 1.48 to 8.24, *P*=0.004).

239 Linear regression analysis demonstrated a consistent effect on minimum LVEF

12

conferred by carrying a TTNtv without attenuation in the AFR population group [Figure
3B]. We conclude that when individuals are artificially grouped by genetic similarity to a
reference population, hiPSI TTNtvs continue to associate with a diagnosis of DCM and
negatively associate with decreased minimum LVEF across diverse groups.

245 Effect of titin truncating variants on risk of atrial fibrillation

246 To test the effect of TTNtvs on risk of Afib, another cardiovascular diagnosis 247 previously shown to associate with TTNtvs, we used logistic regression analysis by GD 248 and by genetically similar group. Among those individuals closest to the 1000G 249 European centroid by GD, hiPSI TTNtvs were associated with Afib (Decile 1 OR = 2.68, 250 95% CI 1.40 to 5.16, P=0.003) [Supplemental Figure 3A]. While there was increased 251 variability across deciles (deciles 2,4, and 5 had statistically insignificant associations between hiPSI TTNtvs and Afib, $I^2=40\%$, $\chi^2=14.96$, P=0.09), there was no significant 252 253 trend in effect as GD from the 1000G European centroid increased (Decile 10 OR = 254 4.36, 95% CI 2.21 to 8.61, P<0.001). When PMBB individuals were grouped by genetic 255 similarity to a reference population, the effect estimate among individuals genetically 256 similar to the 1000G EUR reference population (OR = 2.11, 95% CI 1.62 to 2.77, 257 P < 0.001) was similar to the effect estimate among individuals genetically similar to the 258 1000G AFR reference population (OR = 1.98, 95% CI 1.02 to 3.85, P=0.04) 259 [Supplemental Figure 3B]. We conclude that TTNtvs associate with increased risk of 260 Afib across diverse populations. 261

13

263 **Discussion**

264 Using continuous genetic distance as an alternative method to investigate the 265 effect of genetic similarity on rare variant cardiovascular disease risk, we demonstrated 266 that hiPSI TTNtvs associated with increased risk of DCM and reduced minimum LVEF 267 across diverse populations. These results were supported when individuals were 268 artificially dichotomized by genetic similarity to reference populations, although the 269 effect estimate among individuals genetically similar to the AFR reference population 270 may be attenuated. We also demonstrated a consistent though less robust effect of 271 hiPSI TTNtvs on risk of Afib across diverse populations.

272 Although genetic epidemiology studies have historically relied on arbitrary cutoffs 273 to differentiate and label populations of similar ancestry, genetic ancestry is more 274 appropriately considered as a continuum due to the degree of admixture even among similar populations.²²⁻²⁴ The question of TTNtv effect among individuals genetically 275 276 similar to the 1000G AFR reference population provided an opportunity to reassess the 277 role ancestry plays in how we approach individual risk in cardiovascular disease. The 278 homogeneity of effect of TTNtvs across deciles of GD from the 1000G European 279 centroid removes barriers constructed by presenting results separated by artificially 280 constructed population subgroups, such as within group variation and small sample 281 size. Future evaluation of monogenic risk of cardiovascular disease may benefit from 282 utilizing a similar approach, which may be more broadly applicable than analyses using 283 genetically similar group dichotomization alone.

These results refine our previous findings that hiPSI TTNtvs are associated with DCM among individuals genetically similar to EUR reference populations in PMBB.

286	Previously, we reported an OR of 18.7 (95% CI 9.1 to 39.4) for DCM among EUR
287	individuals with hiPSI TTNtvs. ⁷ The range of effect estimates in our analysis of risk by
288	GD from the 1000G European centroid was OR 3.3 (95% CI 1.3 to 8.6) to OR 9.4 (95%
289	CI 3.8 to 23.1), and the effect estimate for individuals genetically similar to EUR
290	reference panels was contained within that range (OR 7.6, 95% CI 5.0 to 11.4,
291	P<0.001). The attenuation of effect we observed between our initial publication and the
292	present study may reflect a winner's curse in our initial study, where the initially-reported
293	effect size tends to be over-estimated in genetic association studies. ²⁵ However, the
294	makeup of PMBB has also changed substantially in the past five years such that it is
295	less enriched for cardiovascular disease (6.2% prevalence of DCM previously
296	compared to 2.5% now) due to increasingly broad regional enrollment from centers of
297	primary care which may have had a more meaningful impact on our current results.
298	Our findings also clarify the effect of hiPSI TTNtvs in individuals genetically
299	similar to the AFR reference population. We previously identified no statistically
300	significant effect among PMBB participants genetically similar to the AFR reference
301	population. ⁷ This corroborated other evidence suggesting the possibility of differing
302	effects across diverse populations. ³ Notably, our previous PMBB cohort included only
303	2,123 participants genetically similar to the AFR reference population, 20 of whom
304	carried a hiPSI TTNtv, representing a power of 55% to identify an OR of 3.3, suggesting
305	we were previously underpowered to identify an effect similar to what we presently
306	report. We now identify a significant effect of TTNtvs (OR = 3.5, 95% CI 1.5 to 8.2,
307	P=0.004) in this population. Moreover, when we consider the extent of admixture that
308	exists in this population, the dispersion of PMBB participants genetically similar to the

309	1000G AFR reference population across a range of GD from the 1000G European
310	centroid, and the similar effect estimates across those distances, these findings are
311	convincing that hiPSI TTNtvs confer increased DCM risk among individuals within these
312	GD deciles corresponding to those previously labeled genetically similar to the 1000G
313	AFR reference population.
314	
315	Limitations
316	This work has some limitations. Reliance on electronic health records to establish
317	a diagnosis of DCM may have misclassified a subset of individuals. Similarly, TTEs
318	were not interpreted by a uniform reader. Our cohort is also largely composed of EUR
319	and AFR individuals, limiting generalizability of the GD continuum concept to other
320	genetically similar groups.
321	
322	Conclusion
323	In summary, our updated analysis demonstrates a strong association between
324	hiPSI TTNtvs and DCM across a range of genetic backgrounds, including subjects
325	genetically similar to African reference population. These data suggest that
326	recommendations for genetic testing and counseling should not differ between diverse
327	populations.
328	
329	Acknowledgements, Conflicts of Interest and Disclosures
330	We acknowledge the Penn Medicine BioBank (PMBB) for providing data and
331	thank the patient-participants of Penn Medicine who consented to participate in this

16

332	research program. We would also like to thank the Penn Medicine BioBank team and						
333	Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is						
334	approved under IRB protocol# 813913 and supported by Perelman School of Medicine						
335	at University of Pennsylvania, a gift from the Smilow family, and the National Center for						
336	Advancing Translational Sciences of the National Institutes of Health under CTSA						
337	award number UL1TR001878.						
338	M.G.L. receives research support to his institution from MyOme outside of this						
339	work. S.M.D receives research support to his institution from RenalytixAI and in kind						
340	support from Novo Nordisk, both outside of this work.						
341							
342	Sources of Funding						
343	J.D. is supported by the American Heart Association (23POST1011251). M.G.L.						
344	received support from the Institute for Translational Medicine and Therapeutics of the						
345	Perelman School of Medicine at the University of Pennsylvania, the NIH/NHLBI National						
346	Research Service Award postdoctoral fellowship (T32HL007843), the Measey						
347	Foundation, and the Doris Duke Foundation (2023-0224). Z.A. is supported by the						
348	NIH/NHLBI (R01-HL152446) and the Department of Defense (W81XWH18-1-0503).						
349							

17

351 References

352

373

352		
353	1.	Freiburg A, Trombitas K, Hell W, Cazorla O, Fougerousse F, Centner T,
354		Kolmerer B, Witt C, Beckmann JS, Gregorio CC, et al. Series of exon-skipping
355		events in the elastic spring region of titin as the structural basis for myofibrillar
356		elastic diversity. Circ Res. 2000;86:1114-1121. doi: 10.1161/01.res.86.11.1114
357	2.	Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D,
358		Conner L, DePalma SR, McDonough B, Sparks E, et al. Truncations of titin
359		causing dilated cardiomyopathy. N Engl J Med. 2012;366:619-628. doi:
360		10.1056/NEJMoa1110186
361	3.	Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, Buchan RJ,
362		Walsh R, John S, Wilkinson S, et al. Integrated allelic, transcriptional, and
363		phenomic dissection of the cardiac effects of titin truncations in health and
364		disease. Sci Transl Med. 2015;7:270ra276. doi: 10.1126/scitranslmed.3010134
365	4.	Akinrinade O, Alastalo TP, Koskenvuo JW. Relevance of truncating titin
366		mutations in dilated cardiomyopathy. Clin Genet. 2016;90:49-54. doi:
367		10.1111/cge.12741
368	5.	Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S,
369		Kayvanpour E, Vogel B, et al. Atlas of the clinical genetics of human dilated
370		cardiomyopathy. Eur Heart J. 2015;36:1123-1135a. doi:
371		10.1093/eurheartj/ehu301
372	6.	Akinrinade O, Ollila L, Vattulainen S, Tallila J, Gentile M, Salmenpera P, Koillinen

H, Kaartinen M, Nieminen MS, Myllykangas S, et al. Genetics and genotype-

- 374 phenotype correlations in Finnish patients with dilated cardiomyopathy. *Eur Heart*
- 375 J. 2015;36:2327-2337. doi: 10.1093/eurheartj/ehv253
- 376 7. Haggerty CM, Damrauer SM, Levin MG, Birtwell D, Carey DJ, Golden AM,
- 377 Hartzel DN, Hu Y, Judy R, Kelly MA, et al. Genomics-First Evaluation of Heart
- 378 Disease Associated With Titin-Truncating Variants. *Circulation*. 2019;140:42-54.
- 379 doi: 10.1161/CIRCULATIONAHA.119.039573
- 380 8. McAfee Q, Chen CY, Yang Y, Caporizzo MA, Morley M, Babu A, Jeong S,
- 381 Brandimarto J, Bedi KC, Jr., Flam E, et al. Truncated titin proteins in dilated
- 382 cardiomyopathy. *Sci Transl Med.* 2021;13:eabd7287. doi:
- 383 10.1126/scitranslmed.abd7287
- 384 9. McAfee Q, Caporizzo MA, Uchida K, Bedi KC, Jr., Margulies KB, Arany Z,
- 385 Prosser BL. Truncated titin protein in dilated cardiomyopathy incorporates into
- the sarcomere and transmits force. *J Clin Invest*. 2023. doi: 10.1172/JCI170196
- 387 10. Jordan E, Kinnamon DD, Haas GJ, Hofmeyer M, Kransdorf E, Ewald GA, Morris
- 388 AA, Owens A, Lowes B, Stoller D, et al. Genetic Architecture of Dilated
- 389 Cardiomyopathy in Individuals of African and European Ancestry. *JAMA*.
- 390 2023;330:432-441. doi: 10.1001/jama.2023.11970
- 11. Astore C, Sharma S, Nagpal S, Consortium NIG, Cutler DJ, Rioux JD, Cho JH,
- 392 McGovern DPB, Brant SR, Kugathasan S, et al. The role of admixture in the rare
- 393 variant contribution to inflammatory bowel disease. *Genome Med.* 2023;15:97.
- 394 doi: 10.1186/s13073-023-01244-w
- 12. Lewis ACF, Molina SJ, Appelbaum PS, Dauda B, Di Rienzo A, Fuentes A,
- 396 Fullerton SM, Garrison NA, Ghosh N, Hammonds EM, et al. Getting genetic

19

ancestry right for science and society. *Science*. 2022;376:250-252. doi:

- 398 10.1126/science.abm7530
- 399 13. Busby GB, Kulm S, Bolli A, Kintzle J, Domenico PD, Botta G. Ancestry-specific
- 400 polygenic risk scores are risk enhancers for clinical cardiovascular disease
- 401 assessments. *Nat Commun*. 2023;14:7105. doi: 10.1038/s41467-023-42897-w
- 402 14. Ding Y, Hou K, Xu Z, Pimplaskar A, Petter E, Boulier K, Prive F, Vilhjalmsson BJ,
- 403 Olde Loohuis LM, Pasaniuc B. Polygenic scoring accuracy varies across the
- 404 genetic ancestry continuum. *Nature*. 2023;618:774-781. doi: 10.1038/s41586-
- 405 023-06079-4
- 406 15. Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N,

407 Nielsen JB, Melbye M, Haunso S, Sajadieh A, et al. Rare truncating variants in

408 the sarcomeric protein titin associate with familial and early-onset atrial

409 fibrillation. *Nat Commun*. 2018;9:4316. doi: 10.1038/s41467-018-06618-y

410 16. Corden B, Jarman J, Whiffin N, Tayal U, Buchan R, Sehmi J, Harper A,

411 Midwinter W, Lascelles K, Markides V, et al. Association of Titin-Truncating

412 Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With

413 Dilated Cardiomyopathy and Implanted Defibrillators. *JAMA Netw Open*.

414 2019;2:e196520. doi: 10.1001/jamanetworkopen.2019.6520

415 17. Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M,

- 416 Restrepo-Cordoba MA, Dal Ferro M, Stolfo D, Johnson R, et al. Clinical
- 417 Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating

418 Variants in the TTN Gene. *Circ Heart Fail*. 2020;13:e006832. doi:

419 10.1161/CIRCHEARTFAILURE.119.006832

- 420 18. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, Van
- 421 Hout CV, Habegger L, Buckler D, Lai KM, et al. Inactivating Variants in
- 422 ANGPTL4 and Risk of Coronary Artery Disease. *N Engl J Med.* 2016;374:1123-
- 423 1133. doi: 10.1056/NEJMoa1510926
- 424 19. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, Sirugo G,
- 425 Kember RL, Drivas TG, Dudek SM, et al. The Penn Medicine BioBank: Towards
- 426 a Genomics-Enabled Learning Healthcare System to Accelerate Precision
- 427 Medicine in a Diverse Population. *J Pers Med.* 2022;12. doi:
- 428 10.3390/jpm12121974
- 429 20. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
- 430 variants from high-throughput sequencing data. *Nucleic Acids Res.*
- 431 2010;38:e164. doi: 10.1093/nar/gkq603
- 432 21. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample
- 433 Resource (IGSR) collection of open human genomic variation resources. *Nucleic*
- 434 Acids Res. 2020;48:D941-D947. doi: 10.1093/nar/gkz836
- 435 22. Mathias RA, Taub MA, Gignoux CR, Fu W, Musharoff S, O'Connor TD, Vergara
- 436 C, Torgerson DG, Pino-Yanes M, Shringarpure SS, et al. A continuum of
- 437 admixture in the Western Hemisphere revealed by the African Diaspora genome.
- 438 *Nat Commun.* 2016;7:12522. doi: 10.1038/ncomms12522
- 439 23. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo
- 440 JB, Awomoyi AA, Bodo JM, Doumbo O, et al. The genetic structure and history of
- 441 Africans and African Americans. *Science*. 2009;324:1035-1044. doi:
- 442 10.1126/science.1172257

- 443 24. Gouveia MH, Borda V, Leal TP, Moreira RG, Bergen AW, Kehdy FSG, Alvim I,
- 444 Aquino MM, Araujo GS, Araujo NM, et al. Origins, Admixture Dynamics, and
- 445 Homogenization of the African Gene Pool in the Americas. *Mol Biol Evol.*
- 446 2020;37:1647-1656. doi: 10.1093/molbev/msaa033
- 447 25. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of
- 448 genetic association studies supports a contribution of common variants to
- susceptibility to common disease. *Nat Genet*. 2003;33:177-182. doi:
- 450 10.1038/ng1071
- 451

22

453 **Tables and Figure Legends**

- 454 Table 1: Clinical characteristics of individuals in the Penn Medicine Biobank with
- 455 and without high percentage spliced-in *TTN* truncating variants.

Demographic		hiPSI TTNtv (436)	non-hiPSI TTNtv (43,295)	P-value Difference
Age, median (IQR)	56 (45-67)	57 (45-69)	0.65	
Female Sex, N (%)	184 (42%)	21,723 (50%)	<0.001	
"Genetically Similar" Group, N (%)				
	EUR	330 (75%)	29,626 (68%)	0.002
	AFR	88 (20%)	11,048 (26%)	0.008
	AMR	2 (0.4%)	564 (1.3%)	0.12
	EAS	4 (0.9%)	466 (1.1%)	0.74
	SAS	5 (1.1%)	554 (1.3%)	0.79
	Unknown	7 (1.6%)	1,037 (2.4%)	0.28
Dilated Cardiomyopathy, N (%)		52 (12%)	1,060 (2.4%)	<0.001
Ischemic Cardiomyopathy, N (%)	64 (15%)	5,305 (12%)	0.13	
Atrial Fibrillation, N (%)		89 (20%)	4,831 (11%)	<0.001

456



459 Figure 1: Principal component based clusters of individuals in the Penn Medicine Biobank compared to genetic distance from the 1000 Genomes Project European 460 461 centroid and compared to continental-level clusters of 1000 Genomes Project 462 individuals demonstrating the degree of overlap of different genetically similar **groups.** A-C: Discrete labelling of the position of each individual within the Penn 463 Medicine Biobank (PMBB) colored by genetically similar group based on 1000 464 Genomes Project (1000G) continental-level reference populations in a plot of (A) 465 principal component (PC) 1 versus PC2, (B) PC2 versus PC3, and (C) PC1 versus PC3 466 467 with 1000G European centroid (black dot) identified in each plot. (D) the genetic distance from the 1000G European centroid of each individual within PMBB again 468 colored by genetically similar group based on 1000 Genomes Project (1000G) 469 470 continental-level reference populations. **E-G:** Discrete labelling of the position of each 1000G reference panel individuals colored by continental region with PMBB individuals 471

- 472 represented by grey dots in a plot of (E) PC1 versus PC2, (F) PC2 versus PC3, and (G)
- 473 PC1 versus PC3 with 1000G European centroid (red dot) identified in each plot.



A) Effect of TTNtvs on Risk of DCM

Heterogeneity: $\chi_9^2 = 4.59 \ (P = .87), I^2 = 0\%$



B) Effect of TTNtvs on Minimum LVEF

Heterogeneity: $\chi_9^2 = 15.48 \ (P = .08), I^2 = 42\%$

⁴⁷⁵



Population	OR	(95% CI)	P-value	e			
EUR	7.55	[4.99; 11.42]	< .001	_			
AFR	3.50	[1.48; 8.24]	.004				
Meta-analysis	5.65	[2.72; 11.74]	< .001				_
				0.75 1	1.5		15
						OR (95% CI)	

A) Effect of TTNtvs on Risk of DCM Dichotomized by Genetically Similar Group

Heterogeneity: $\chi_1^2 = 2.52 \ (P = .11), I^2 = 60\%$

B) Effect of TTNtvs on Minimum LVEF Dichotomized by Genetically Similar Group



Heterogeneity: $\chi_1^2 = 4.45 \ (P = .03), I^2 = 78\%$

484

485

Figure 3: Effect of high percentage spliced in TTN truncating variant on risk of 486 487 dilated cardiomyopathy diagnosis and minimum left ventricular ejection fraction 488 reduction stratified by genetically similar group excluding those with ischemic 489 cardiomyopathy in the Penn Medicine Biobank. (A) Logistic regression analysis of 490 the association between hiPSI TTNtvs and DCM diagnosis, and (B) linear regression 491 analysis of the association between hiPSI TTNtvs and minimum left ventricular ejection 492 fraction among individuals genetically similar to the 1000 Genomes Project European 493 and African reference population, and meta-analyzed. OR = odds ratio; CI = confidence 494 interval; EUR = individuals genetically similar to the European reference population; AFR = individuals genetically similar to the African reference population. 495